A major breakthrough in pancreatic cancer research has captured international attention this week, following the presentation of results from Revolution Medicines' RASolute 302 clinical trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The findings, which received a standing ovation from delegates, mark a significant milestone in a research journey more than 15 years in the making. For a disease where progress has often been measured in small steps, these results represent something profoundly important: real momentum and renewed hope for people affected by pancreatic cancer.
Earlier this month, Revolution Medicines announced positive results from its Phase 3 RASolute 302 trial evaluating daraxonrasib, a targeted therapy for people with previously treated metastatic pancreatic cancer.
The results were remarkable. People who received daraxonrasib experienced a median overall survival of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy. The treatment also demonstrated a 60 per cent reduction in the risk of death.
RAS mutations are present in approximately 90 per cent of pancreatic cancer cases, making them one of the most common genetic drivers of the disease. Daraxonrasib has been designed to target a broad range of RAS mutations, creating the potential to improve outcomes for people diagnosed with pancreatic cancer while also informing future treatments across multiple cancer types.
For a disease that has seen limited advances in treatment over recent decades, these results are an important reminder of what sustained investment in research can achieve.
Daraxonrasib is now available to eligible people in the United States, providing access to a treatment that could significantly extend survival for some people living with advanced pancreatic cancer.
While this announcement is encouraging, it is not the finish line.
Researchers are already investigating daraxonrasib in first-line treatment settings, while additional studies are exploring combination approaches that may further improve outcomes. The scientific insights gained through this work are also expected to accelerate the development of future targeted therapies.
Working towards access for Australians
For Australians affected by pancreatic cancer, the focus now turns to access.
This treatment represents genuine progress. But progress only matters if people can benefit from it.
"Pankind's focus now is to help ensure Australians can access this promising new treatment as quickly as possible. We are committed to working with clinicians, researchers, policymakers and industry to help close the gap between discovery and access, because everyone affected by pancreatic cancer deserves a fair chance," - Michelle Stewart, CEO Pankind
Securing Australian registration for daraxonrasib will require Revolution Medicine to progress through local regulatory pathways. While Pankind cannot control that process, we are committed to using every avenue available to help drive momentum and advocate for timely access.
We are engaging clinicians, regulators, government stakeholders and international partners to ensure pancreatic cancer remains part of the conversation and that opportunities to improve access are explored wherever possible.
There is still a long road ahead, and no single breakthrough will transform outcomes on its own. But the RASolute 302 results show that progress is possible when researchers, clinicians, advocates, funders and communities work together with a shared purpose.
They are also a powerful reminder that investment in pancreatic cancer research changes what is possible.
Pankind remains committed to funding research, supporting innovation and advocating for access to promising new treatments. Because people affected by pancreatic cancer should not have to wait longer than necessary for advances that could improve outcomes.
While access to daraxonrasib in Australia is still being pursued, some people may wish to explore whether a clinical trial could be an option. Pankind's Support Navigator, Dianne, is available to answer questions, provide guidance and help connect people and families with relevant information and support.
Today, we also acknowledge those who have lost their lives to pancreatic cancer, and the families and friends who continue to carry their memory forward. Their experiences are a powerful reminder of why progress cannot pause.
This breakthrough offers real hope. Now we must build on it.
